Gene silencing and gene editing

Engineered Cas clears barrier to antiviral CRISPR therapies

By Nick Paul Taylor

Researchers have engineered a Cas enzyme to enhance activity against RNA viruses, resulting in a system that completely blocked the replication of various SARS-CoV-2 strains.

April 19, 2024

Gene-based technique shows potential for rapid diagnostics

By LabPulse.com staff writers

Biomedical engineers have developed a new gene-based approach which can be used on test strips for rapid, on-the-spot disease detection with accuracy comparable to that of lab-based polymerase chain reaction (PCR) tests.

March 7, 2024

Reversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapy

By Nick Paul Taylor

A CRISPR system that uses Cas13d to make reversible changes to the expression of multiple genes could overcome limitations that are holding back CAR-T cell therapies, a paper published in Cell suggests.

February 28, 2024

Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF

By LabPulse.com staff writers

Gene-editing firm Intellia Therapeutics and biotech company ReCode Therapeutics have entered into a strategic collaboration aimed at developing genomic medicines for the treatment of cystic fibrosis (CF).

February 16, 2024

CRISPR and nanopore technology enable sensitive and specific mpox detection

By Nick Paul Taylor

A test that combines CRISPR gene editing and nanopore sensing technology could accelerate the detection of mpox and other pathogens, according to a paper published in Biosensors and Bioelectronics.

February 16, 2024

Sensorion receives clinical trial approval for congenital deafness gene therapy

By LabPulse.com staff writers

French biotech firm Sensorion has received approval to initiate a phase I and II clinical trial in France of SENS-501 (the OTOF-GT program), its gene therapy for gene-mediated hearing impairment.

January 22, 2024

First FDA-approved CRISPR-based gene therapy cleared for 2nd indication

By LabPulse.com staff writers

A month after the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, the agency has given it a second U.S. regulatory approval ahead of schedule.

January 17, 2024

Genevant Sciences forges $114M deal with Tome Biosciences on liver disease gene therapy

By LabPulse.com staff writers

Biotech firm Genevant Sciences will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.

January 16, 2024

IGI, Danaher launch CRISPR gene therapy research center

By LabPulse.com staff writers

Danaher and the Innovative Genomics Institute (IGI) have launched a collaborative research center aimed at developing CRISPR-based gene therapies for a wide array of diseases.

January 12, 2024

Gene therapy, companion diagnostic hit milestones for hemophilia A

By Liz Carey

Six months after the FDA approved a one-time gene therapy for severe hemophilia A reportedly priced around $2.5 million per patient, the Center for Inherited Blood Disorders, a 340B treatment center in California, has announced the drug's first infusion.

January 11, 2024

Tome Biosciences acquires Replace Therapeutics in $65M deal

By LabPulse.com staff writers

Less than a month after Tome Biosciences emerged with $213 million in funding, the gene editing company will acquire Replace Therapeutics for $65 million in upfront and near-term milestones, with a total deal value of up to $185 million.

January 5, 2024

KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy

By LabPulse.com staff writers

Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.

November 29, 2023

Page 1 of 7

Next Page